In tumors harboring the V600E mutation, BRAF seems to be the key proliferation driver [37]; thus, vemurafenib causes dramatic tumor shrinkage in patients with V600E-mutated tumors but not in tumors wild-type for BRAF [38]. The gene discussed is BRAF; the disease is neoplasm.